Generic Rx Delays Could Result From House Medicare Provisions, GPhA Says

A provision on the "antibundling" of generic drug applications in the House Medicare prescription drug bill could be misused by the brand name industry to delay the market entry of generics, the Generic Pharmaceutical Association says